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ABSTRACT The effectiveness of drugs is often limited by
their insufficient selectivity. I propose designs of therapeutic
agents that address this problem. The key feature of these
reagents, termed comtoxins (codominance-mediated toxins), is
their ability to utilize codominance, a property characteristic
of many signals in proteins, including degradation signals
(degrons) and nuclear localization signals. A comtoxin de-
signed to kill cells that express intracellular proteins P1 and
P2 but to spare cells that lack P1 and/or P2 is a multidomain
fusion containing a cytotoxic domain and two degrons placed
within or near two domains P1* and P2* that bind, respec-
tively, to Pl and P2. In a cell containing both P1 and P2, these
proteins would bind to the P1* and P2* domains of the
comtoxin and sterically mask the nearby (appropriately po-
sitioned) degrons, resulting in a long-lived and therefore toxic
drug. By contrast, in a cell lacking Pl and/or P2, at least one
of the comtoxin's degrons would be active (unobstructed),
yielding a short-lived and therefore nontoxic drug. A comtoxin
containing both a degron and a nuclear localization signal
can be designed to kill exclusively cells that contain P1 but
lack P2. Analogous strategies yield comtoxins sensitive to
the presence (or absence) of more than two proteins in a cell.
Also considered is a class of comtoxins in which a toxic
domain is split by a flexible insert containing binding sites
for the target proteins. The potentially unlimited, combi-
natorial selectivity of comtoxins may help solve the problem
of side effects that bedevils present-day therapies, for even
nonselective delivery of a comtoxin would not affect cells
whose protein "signatures" differ from the targeted one.
Abnormal cells differ from their normal progenitors and other
cells of the same organism in a variety of ways, including
protein composition. For example, virus-infected cells contain
virus-specific proteins; the levels of certain cellular proteins
are also altered as a result of viral infection. Cancer cells, which
can grow at sites of their initial emergence and at distant sites
that they are capable of colonizing, differ from their normal
progenitors in the patterns of gene expression. Some of the
tumor-specific proteins are altered versions of normal pro-
teins, in that they are encoded by genes whose mutations were
among the causes of a malignant phenotype (1-3).
A viral genome encodes relatively few proteins. In part
because most of these proteins have functional counterparts in
cells that the virus infects, effective antiviral drugs remain, by
and large, a goal to be reached (4). With malignant tumors that
cannot be eliminated by surgery alone, the problem of finding
a drug up to the task is even more complicated, because
compositional differences between a tumor cell and its normal
progenitor can be subtle and quantitative rather than quali-
tative. In addition, cells of a tumor are often heterogeneous
genetically and in protein composition (1-4). These are some
of the reasons for the failure of present-day therapies to cure
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most cancers. A major limitation of cytotoxic treatments is
their low selectivity for tumor cells. For example, radiation
therapy and alkylating agents perturb many functions that are
common to most cells. As for the current single-target drugs,
for example, methotrexate and vinblastine (4), the problem is
not only the distribution of their ligands (dihydrofolate reduc-
tase and tubulin), which are present in both normal and
malignant cells, but also the constraint that a single molecular
target is often insufficient for defining unambiguously enough
the cell type to be eliminated.
A recent approach to improving the selectivity of drugs
involves the linking of a toxin to an antibody or another ligand
(e.g., a growth factor) that binds to a target on the surface of
tumor cells. The tumor selectivity of these reagents, called
immunotoxins or chimeric toxins, is often higher than that of
small cytotoxic drugs (5, 6). Unfortunately, a surface marker
that an immunotoxin recognizes may be present not only on
target cells. Moreover, since this marker is often not essential
for tumorigenicity, there may be cells in a tumor that lack the
marker but are still malignant. These are some of the limita-
tions of present-day immunotoxins (5, 6).
Yet another approach is to increase or redirect the power of
the immune system to identify and selectively destroy tumor
cells. Immunotherapy of cancer has a long and checkered
history. The recent revival of this strategy (7), brought about
by advances in the understanding of antigen presentation and
lymphocyte-mediated cell killing, holds the promise of a
rational and curative therapy. Since this goal remains to be
reached, it is still far from certain that intelligent manipulation
of the immune system will prove sufficient for a complete and
assured cure of most cancers.
Might there be a generally applicable strategy for eliminat-
ing (or modifying) dangerous cells that is distinct from the
existing approaches? Described below are the concepts of such
a strategy.
Indelins: Comtoxins That Bear Degradation Signals. The
main idea of this work is that the property of codominance,
possessed by many signals in proteins and other biopolymers,
can be utilized to produce therapeutic agents of previously
unattainable selectivity. Figs. 1-4 illustrate the designs of these
reagents, termed comtoxins (codominance-mediated toxins).
We begin by considering comtoxins that utilize degradation
signals (degrons). These comtoxins are termed indelins (in-
tracellular degron-dependent, ligand-regulated toxins). The
crucial property of an indelin is that its intrinsic activity-e.g.,
toxicity-is the same in all cells, whereas its half-life (and,
consequently, its steady-state level and overall toxicity) in a cell
depends on the cell's protein composition, specifically on the
presence of two or more proteins that have been chosen to
define the profile of a cell to be eliminated (Fig. 1). The
metabolic instability of indelins and the possibility of control-
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Cell type State of [P1+ P2+J-indelin
P1 P2 short-lived
~~~~~P (nontoxic)
P1+ P2 Pi short-lived
Pl1 P2+ ;>short-lived
P1+ P2+ long-lived
J ! 111 (toxic)
FIG. 1. An indelin (intracellular degron-dependent, ligand-
regulated toxin) designed to kill P1+P2+ cells (cells that express
proteins P1 and P2) but to spare the other cell types (P1+P2-, P1 -P2+,
and P1-P2-) contains a cytotoxic effector domain (see text) and two
degradation signals (degrons), dl and d2, placed within or near two
domains P1* and P2* that bind, respectively, to P1 and P2. In cells
other than P1 +P2+, at least one of the indelin's degrons, dl and/or d2,
is active (unobstructed), resulting in a short-lived and therefore rela-
tively nontoxic indelin. By contrast, in P1+P2+ cells both dl and d2
would be masked by P1 and P2 (bound, respectively, to the indelin's
P1* and P2* domains), resulting in a long-lived and therefore toxic
indelin. This design requires that P1, P2, and the indelin reside in the
same compartment, the one in which the indelin's toxic domain exerts
its effect. In addition, the degrons dl and d2 must be active in the
relevant compartment; they may or may not be identical-the design
is compatible with either choice.
ling this instability result from the presence of appropriately
positioned degrons. A degron is an amino acid sequence, a
conformational determinant, or a chemically modified protein
structure that renders a protein short-lived (8). The concept of
indelins stems from the following property of degradation
signals: each degron in a short-lived protein bearing two or
more degrons can function independently of other degrons in
the same protein; i.e., multiple degrons of a protein can be
codominant.
An indelin designed to kill cells that express proteins P1 and
P2 but to spare cells that lack P1 and/or P2 (Fig. 1) is a
multidomain fusion containing a cytotoxic effector domain
(for example, a ricin or a Pseudomonas toxin; see below) and
two degrons placed within or near two domains P1* and P2*
that bind, respectively, to P1 and P2. An indelin is delivered
into cells via routes employed with immunotoxins (5, 6) or
through the use of expression vectors (more about this below).
In a cell containing both P1 and P2, these proteins would bind
to their respective ligands P1* and P2* in the indelin molecule
and sterically mask the nearby (appropriately positioned)
degrons, resulting in a long-lived and therefore toxic indelin.
By contrast, in a cell lacking P1 and/or P2, at least one of the
indelin's degrons would be active (unobstructed), yielding a
short-lived and therefore relatively nontoxic indelin (Fig. 1).
For an indelin (or another comtoxin) to be effective, the
differences among cells in their levels of P1 and P2 proteins
need not be all-or-none. Specifically, these differences should
be large enough to cause the concentration of indelin (within
the temporal window of a treatment) to be lethal in a targeted
cell population but lower than lethal in cells containing smaller
amounts of P1 and/or P2. Since other biopolymers, for exam-
ple, RNA, can also fold into ligand-binding domains and bear
signals such as degrons, nucleic acid-based comtoxins should
be feasible as well.
Codominance of Degrons. The best understood intracellular
degradation signal, called the N-degron, comprises a destabi-
lizing N-terminal residue and an internal lysine (or lysines) of
a protein substrate (8). A set of N-degrons bearing different
destabilizing residues is referred to as the N-end rule-a rela-
tion between the metabolic stability of a protein and the
identity of its N-terminal residue (8). The in vivo half-life of a
protein bearing a strongly destabilizing N-terminal residue
such as arginine can be as short as 1 min, whereas an otherwise
identical protein bearing a stabilizing N-terminal residue such
as valine has a half-life of >20 hr, resulting in a >1000-fold
difference between the steady-state concentrations of these
proteins (8). The lysine residue of an N-degron is the site of
formation of a multiubiquitin chain, which is required for the
substrate's degradation by the 26S proteasome-a multicata-
lytic, multisubunit protease (9). Ubiquitin is a protein whose
covalent conjugation to other proteins plays a role in a number
of processes, primarily through routes that involve protein
degradation (8, 9). At least one of the naturally short-lived
proteins, the yeast Mata2 transcriptional repressor, bears two
degradation signals located in two different regions of Mata2
and targeted by two distinct ubiquitin-dependent pathways
(10).
This mechanistic understanding, while still rudimentary, is
sufficient for concluding that spatially distinct degrons in the
same intracellular protein can be codominant-i.e., that they
can target the protein for degradation independently of each
other. The property of codominance underlies the concept
of indelins (Fig. 1). Another feature of ubiquitin-dependent
pathways that is also central to the concept of indelins is
processivity, the ability of these pathways to initiate and
complete the degradation of a protein to short peptides after
recognizing a protein's degron (8, 9).
Intralins: Comtoxins That Bear Translocation Signals. The
property of codominance is not confined to degradation
signals. For reasons analogous to those considered above for
degrons, the signals that confer on a protein the ability to enter
membrane-enclosed compartments (11, 12) should be able to
function independently of each other if they are present in
spatially distinct regions of the same protein. Comtoxins that
utilize translocation signals are termed intralins (intracellular
translocation signal-dependent, ligand-regulated toxins). The
discussion below is confined to intralins that bear nuclear
localization signals (NLSs).
Proteins smaller than "60 kDa can enter the nucleus by
diffusing through the nuclear pores, but the pore-mediated
transport of a larger protein requires the presence of at least
one NLS accessible to components of the nuclear translocation
system (12). NLSs are short sequences (10-20 residues) rich in
lysine and arginine; their steric accessibility in a target protein
appears to be sufficient for their activity as nuclear translo-
cation signals (12). Many NLS-bearing proteins enter the
nucleus shortly after their synthesis in the cytosol, but the
transport of some proteins is not constitutive: their NLSs have
to be "activated," often by unmasking sterically shielded NLSs
(12-14).
An example of a NLS-bearing intralin is a fusion containing
an effector domain that is toxic in the cytosol but not in the
nucleus (see below), and two NLSs placed within or near two
domains P1* and P2* that bind, respectively, to P1 and
P2-cytosolic proteins that define the target specificity of the
fusion (Fig. 2A). If the cell's cytosol contains both P1 and P2,
these proteins would bind to their respective ligands P1* and
P2* in the intralin molecule and sterically mask the nearby
(appropriately positioned) NLSs, resulting in a cytosolic and
therefore toxic intralin (Fig. 2A). By contrast, if the cell's
cytosol lacks P1 and/or P2, at least one of the intralin's NLSs
would be active (unobstructed), resulting in a nuclear and
therefore relatively nontoxic intralin.
Toxic proteins whose substrates are located in the cytosol
but not in the nucleus include the diphtheria toxin and the
Pseudomonas exotoxin A, both of which inhibit protein syn-
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FIG. 2. (A) An intralin (intra-
cellular translocation signal-depen-
dent, ligand-regulated toxin) de-
signed to kill exclusively P1+P2+
cells contains a cytosol-specific ef-
fector domain and two NLSs,
placed within or near two domains
P1* and P2*, that bind, respec-
tively, to proteins P1 and P2, which
must be located at least in the
cytosol. (B) An intralin whose toxic
domain is nucleus-specific would
kill P1+P2-, P1-P2+, and P1-P2-
cells but would spare P1 +P2+ cells.
thesis by ADP-ribosylating (and thereby inactivating) elonga-
tion factor 2 (5, 6). Since the bulk of elongation factor 2 is
cytosolic, the translocation of intralin containing a Pseudomo-
nas-type toxic domain from the cytosol to the nucleus would
physically separate a toxin from its substrate.
Inverting the Selectivity of an Intralin. An intralin analo-
gous to the one above but bearing an effector domain that is
toxic in the nucleus but not in the cytosol (see below) would
kill cells that lack P1 and/or P2-the selectivity opposite to
that of the intralin considered above (Fig. 2A vs. Fig. 2B). The
ability to target cells that lack a set of predetermined proteins
is important because cancer cells lack (or contain functionally
inactive versions of) certain regulatory proteins ("tumor sup-
pressors") that are present in the normal progenitors of these
cells (1-3).
Indelins and Intralins Bearing a Single P*-Type Domain.
Counterparts of constructs in Figs. 1 and 2 that bear a single
P*-type domain can function as indelins or intralins; however,
these new drugs are not yet comtoxins (the mechanics of
codominance requires more than one P*-type domain). At the
same time, the ligand-controlled toxicity of these drugs would
be analogous to that of comtoxins. Thus, in addition to being
an intermediate in the construction of a comtoxin, an indelin
or intralin bearing a single P*-type domain can be used as a
drug specific for a single intracellular target.
Combinatorial Selectivity of Hybrid Comtoxins. Consider
a comtoxin that contains an effector domain which is toxic
in the nucleus but not in the cytosol, a degron placed within
or near domain P1*, and a NLS placed within or near domain
P2* (Fig. 3). As before, the P1* and P2* domains should be
able to bind, respectively, to intracellular proteins P1 and P2.
In contrast to a "pure" indelin or intralin (Figs. 1 and 2), this
"hybrid" comtoxin would kill exclusively cells that contain
nuclear protein P1 but lack cytosolic protein P2, for only in
such cells would the comtoxin be both nuclear (because its
NLS is not masked, owing to the absence of P2) and
long-lived (because its degron is masked by the P1-P1*
complex) (Fig. 3). (The constraints on localization of P1 and
P2 are actually less stringent than stated here; see Fig. 3
legend.)
Nucleus-specific effectors include deoxyribonucleases, ei-
ther relatively nonspecific ones or restriction endonucleases.
Indeed, EcoRI has been shown to cleave nuclear DNA in vivo
(in the yeast Saccharomyces cerevisiae), killing the cells (15).
Split Comtoxins. Fig. 4 illustrates the idea of a ligand-
sensitive split toxin. A single-domain protein whose subdo-
mains are separated by a conformationally flexible insert can
adopt a (nearly) normal conformation, in which the insert is
extruded to the outside of the folded domain. For example, the
in vivo folding of ubiquitin, a 76-residue protein, was shown to
be virtually unperturbed by the insertion of an unrelated
80-residue sequence at a site between the two subdomains of
ubiquitin (16). The idea of a split comtoxin (Fig. 4) stems from
these and analogous data (cited in ref. 16) and also from the
notion that the extent of conformational flexibility of an insert
between two subdomains of a protein should influence the
protein's folding. In particular, a conformationally rigid insert
would be expected to perturb or preclude the coalescence of
the protein's subdomains.
In Fig. 4, two subdomains of a toxic domain are separated
by a sequence that contains a binding site (P1*) for an intra-
cellular protein P1. Unlike the P1 * domains of other comtoxins
(Figs. 1-3), the P1* site of a split toxin (Fig. 4) should be a
relatively short (peptide-size) region that remains conforma-
tionally flexible unless it is bound by P1. The construct of Fig.
4 would be toxic in cells that lack P1 but relatively nontoxic in
P1-containing cells. For a split toxin to work, the affinity
between subdomains of a toxic domain should be low enough
to make their interaction substantially reversible, precluding
irreversible activation of the toxic domain before its encounter
with P1 (Fig. 4). This affinity can be adjusted, if necessary,
FIG. 3. A hybrid comtoxin that bears signals utilized in both
indelins and intralins (Figs. 1 and 2) contains an effector domain that
is active in the nucleus but not in the cytosol (see text), a degron placed
within or near domain P1*, and a NLS placed within or near the
domain P2*. P1* and P2* bind, respectively, to intracellular proteins
P1 and P2. As described in the diagram, this comtoxin would kill
exclusively P1+P2- cells. In these cells, P1 must be located at least in
the nucleus, whereas P2 must be a cytosolic protein. Another con-
straint is that the degron dl must be active at least in the nucleus. The
actually indicated state of comtoxin in P1+P2+ cells requires that P1
is present in both the cytosol and the nucleus and that the degron dl
is active in both of these compartments. If P1 is present largely in the
nucleus, or if dl is active only in the nucleus, the metabolic properties
of this comtoxin would differ from those indicated, but its selectivity
(killing exclusively P1+P2- cells) would remain the same.
Cell type A State of [P1+ P2+]-intralin B State of [P1 P2 ]-intralin
Pl1P2 <z;;z+, nuchearzzb-nuclear(nontoxic) i (toxic)
Pi+ P2- nuclear 1 nuclearP2 ! (nontoxic) (toxic)
|Pl1P2+ |nuclear n(uclea)r|
P1+ P2+> cytosolicP1 P2 P1c (toxic)Polc (nontoxic)
Cell type State of [P1+ P2-]-comtoxin
- e l short-lived,
P1 P2 nuclear(nontoxic)
9 long-lived,
Pi+ P2_ pi nuclear
(toxic)
short-lived,
Pf P2+ cytosoliclP2* &u& (nontoxic)
_rsF _long-lived,
P1+ P2+ pi* cytosolic
(nontoxic)
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inactive toxin
FIG. 4. Split toxin. In this design, two subdomains of a toxic
effector domain are separated by an insert whose sequence contains
a binding site for an intracellular protein P1. Unlike the P1* domains
of comtoxins in Figs. 1-3, the P1-binding site of a split toxin is a
relatively short (peptide-size) region that remains conformationally
flexible unless it is bound by P1. For this design to work, the affinity
between subdomains of a toxic domain should be low enough to make
their interaction substantially reversible (see text). A flexible insert
between subdomains of a toxin can also contain two binding sites for
intracellular proteins P1 and P2, arranged so that the binding of either
P1 or P2 would be sufficient to impair the reconstitution of active
toxin. The resulting comtoxin would kill exclusively cells that lack both
P1 and P2.
through mutational alterations analogous to those that have
been used with the subdomains of ubiquitin (16). An insert of
a split toxin can also bear more than one protein-binding site,
in which case the codominance of these sites would result in a
split comtoxin (see Fig. 4 legend). More elaborate versions of
split comtoxins that bear elements of indelins or intralins
should be feasible as well.
Elimination of Defective Organelles. Mutations accumulate
in the mitochondrial DNA (mtDNA) at a much higher rate
than in the nuclear DNA (17). Since almost every cell in a
metazoan organism harbors hundreds of mitochondria, their
intracellular populations are genetically heterogeneous ("het-
eroplasmic"). Mutations in mtDNA that occur in the female
germ line are transmitted to the progeny. The resulting defects
are implicated in >100 human diseases, many of them severe
(17). Mutations in mtDNA of somatic cells accumulate during
the lifetime of an organism and perturb the functions of
mitochondria, including the synthesis ofATP. These mutations
are among the causes of time-dependent decline in the per-
formance of organs that is the hallmark of aging (18).
Disruptive effects of malfunctioning organelles are beyond
the reach of current therapies. Remarkably, this problem
might become addressable with comtoxins that utilize the
mitochondrial translocation pathway (11) to enter mitochon-
dria and selectively destroy those among them that no longer
produce a "required" amount of ATP. The likely common
features of defective mitochondria include elevated levels of
mitochondrial stress proteins. A mitochondrial comtoxin can
be, for example, an indelin containing a mitochondrial prese-
quence (11), a toxic effector domain, domains P1* and P2* that
bind to mitochondrial stress proteins P1 and P2 (whose levels
are low in the normal mitochondria but high in defective ones),
and mitochondrial degrons that are sterically masked upon the
binding of P1 and P2 to the P1* and P2* domains of the indelin.
[Mitochondrial proteolytic systems are analogous, but not
identical, to those of the cytosol (19); intramitochondrial
degrons remain to be identified.] A therapeutically relevant
elimination of a mitochondrion would not necessarily entail its
physical destruction. Instead, it may be sufficient if the toxin
halts the growth and multiplication of a defective mitochon-
drion and also renders it "invisible" to the system that controls
the total amount of mitochondria in a cell, thereby allowing
compensatory growth and multiplication by surviving (less
defective) mitochondria.
Effector Domains. The A chain of ricin and analogous plant
toxins, which act as N-glycosidases specific for certain sites in
rRNA, inactivate ribosomes in the cytosol (5, 6) and are also
likely to be active with immature ribosomes of the nucleus.
Other examples of toxins whose substrates are present in both
the cytosol and the nucleus include ribonucleases such as
RNase A and barnase, which have been used to produce
chimeric toxins (6).
Designs of intralins (Fig. 2), hybrid comtoxins (Fig. 3), and
split comtoxins (Fig. 4) require effectors that are toxic exclu-
sively in the cytosol or exclusively in the nucleus. Examples of
such effectors were discussed above. Since the goal of therapy
is to render dangerous cells harmless, the set of useful effector
domains is not confined to cytotoxic proteins; it may include,
for instance, transcription factors whose presence in a cell
results in growth arrest and terminal differentiation.
Designing P*-Type Domains. These domains of a comtoxin
(Figs. 1-3) bind to specific intracellular proteins (P1, P2, etc.).
A homodimerization of P*-type domains is undesirable be-
cause it would interfere with the function of a comtoxin. Thus,
a P*-type domain should be able to form a heterodimer with
its intracellular partner (a P1-type protein) while not forming
a high-affinity homodimer. Possible designs of a P*-type
domain include the following.
(i) A natural protein ligand of a P1-type protein.
(ii)A peptide-size fragment of the natural ligand that retains
affinity for a P1-type protein (Fig. 4).
(iii) A single-chain antibody (5, 6) specific for a P1-type
protein. This class of P*-type domains includes single-chain
antibodies to the junctional regions of tumor-specific fusion
proteins produced by tumorigenic chromosome translocations
(1-3). These mutant proteins form early in the evolution of a
tumor cell lineage, are likely to be required for the malignant
phenotype (2), and therefore are an especially pertinent class
of P1-type proteins.
(iv) A nonpeptide, low molecular weight ligand of a P1-type
protein. This possibility is confined to directly delivered (as
distinguished from expression-based) comtoxins.
Target Cells and Intracellular Ligands. The detailed pro-
tein composition of specific cell types, in particular of normal
and tumor-derived human cells, is being determined by a
number of laboratories, but the information gathered thus far
is still sketchy for most cell types. Therefore a useful short-term
strategy would be to choose the intracellular ligands of a
comtoxin from a set of intracellular proteins that are already
known to be either overproduced in the target cells or absent
from them; the latter proteins should be present in most (not
necessarily all) nontarget cells.
Consider a tumor cell lacking the wild-type version of a
tumor-suppressor protein (expressed in the normal progeni-
tors of this cell) and overproducing another protein, perhaps
as a result of a gene amplification that contributed to the cell's
malignant phenotype. For example, many (but not all) human
breast carcinomas lack the tumor-suppressor protein p53 or
contain its functionally inactive variants (3). Further, many of
these tumors overproduce the protein c-Myc (in addition to
several other proteins) (3). A comtoxin that kills cells which
contain a P1 protein but lack a P2 protein has the requisite
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selectivity for such a setting. The comtoxin's P1* domain
would bind to c-Myc, while the comtoxin's P2* domain would
bind to wild-type p53 but not to its mutant variant in a given
carcinoma. Even nonselective intracellular delivery of this
comtoxin would kill Myc-overexpressing, p53-lacking carci-
noma cells but spare most, if not all, other cells of the organism,
because most normal cells contain p53; the few, if any, normal
cell types that lack p53 are unlikely to overproduce c-Myc
(1-3). Moreover, the selectivity of this comtoxin can be
increased further, if necessary, by adding to it a degron- or
NLS-containing P3* domain that binds to a third intracellular
protein, P3, chosen to sharpen the description of target cells.
This example illustrates strategies that can be used to select
an optimal set of intracellular ligands for comtoxins against
specific cancers, against cells infected by a specific virus, or
against other undesirable cells. Examples of the latter are cells
that form atherosclerotic plaques, and cells of neovascular
endothelium, whose selective ablation would cut off the blood
supply to a metastatic tumor (20).
Delivery to Targets. For delivery via the intravascular route
(4), a comtoxin should possess not only a toxic domain but also
a domain that mediates the translocation of a fusion from the
cell surface to the cytosol. This aspect of comtoxins is confined
to direct-delivery (as distinguished from expression-based)
strategies and is similar to the analogous aspects of current
immunotoxins (5, 6). Comtoxins can also be delivered into cells
through the intermediacy of expression vectors. Both of these
approaches are a part of ongoing efforts to improve bioavail-
ability of protein drugs used in medical interventions, from
cytotoxic treatments to gene therapies (5, 6, 21, 22). The
problem of insufficient selectivity is common to all of the
current cytotoxic strategies: once the effector reaches its
intended intracellular compartment, the cell is likely to be
killed irrespective of whether it was a target or an innocent
bystander. For example, one drawback of the current immu-
notoxins is their nonspecific toxicity-largely, but not only,
to the liver (5, 6). This toxicity, which imposes a limit on both
duration and intensity of treatments, stems in part from
the clearance of an intravenously administered immunotoxin
by cells of the reticuloendothelial system (5). By contrast,
even nonselective delivery of a comtoxin (Figs. 1-3) would
not affect most nontarget cells.
Comtoxins designed for delivery by an expression vector
would lack the "compartment-crossing" domain required for
their directly delivered counterparts. Recent advances in the
design of viral and plasmid-based vectors are bringing closer
the possibility of tailor-made, nonreplicating vectors that can
transfect both growing and quiescent cells, elicit little or no
immune response, and are either specific for cells that bear a
predetermined surface marker or almost nonselective. Such
vectors, under development for gene therapy and other appli-
cations (21, 22), should also yield powerful methods for the
delivery of comtoxins.
Concluding Remarks. The main idea of this work is that the
property of codominance, characteristic of signals such as
degrons and NLSs, can be utilized to produce a new class of
therapeutic agents-indelins, intralins, and other comtoxins
(Figs. 1-4). A feature of these reagents is their potentially
unlimited, combinatorial selectivity for targets that can be
either whole cells or specific organelles. The sources of this
selectivity are distinct from mechanisms that underlie immu-
nological recognition, suggesting that comtoxins can be de-
signed to do things that the immune system cannot. For
example, even if the immune system will someday be harnessed
to eliminate any set of undesirable cells in an organism without
injuring other cells-a most optimistic assumption-there
would still be the problem of "rejuvenating" otherwise normal
cells by selectively destroying their defective organelles. As
discussed above, a cell-level approach would be inadequate
here, because every cell in an aging organism contains both
healthy and defective mitochondria. This and analogous prob-
lems are not considered in the context of therapy today but may
become addressable through the development of comtoxin
technology. Meanwhile, the nearest testing grounds for this
approach will be cell-specific therapies, in which comtoxins are
directed against virus-infected and cancer cells.
The features that set comtoxins apart from earlier thera-
peutic agents are the potentially unlimited selectivity of a
comtoxin and the possibility of incremental increases in se-
lectivity through the use of the same strategy that yielded a
preceding, less selective drug. If the properties of comtoxins
live up to the premise of their design, this approach may help
eliminate the problem of side effects-the bane of today's
therapies-for even nonselective delivery of a comtoxin would
not affect cells whose protein "signatures" differ from the
targeted one.
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